Eone Diagnomics Genome CenterEDGC
245620 · KOSDAQ · ₩245620 · EDGC
₩741 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩7.9B | ₩31B | ₩88B | ₩94B | ₩89B |
| Cost of sales | ₩4.8B | ₩25B | ₩79B | ₩81B | ₩80B |
| Gross profit | ₩3.1B | ₩5.6B | ₩9.9B | ₩13B | ₩9.2B |
| Operating income | −₩1.6B | −₩13B | −₩9.4B | −₩9.5B | −₩16B |
| Net income | ₩28B | −₩95B | −₩33B | −₩30B | −₩21B |
| Net income to shareholders | ₩28B | −₩95B | −₩33B | −₩30B | −₩21B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩44B | ₩86B | ₩174B | ₩192B | ₩187B |
| Current assets | ₩19B | ₩45B | ₩46B | ₩42B | ₩59B |
| Cash and equivalents | ₩13B | ₩9.5B | ₩9.4B | ₩4.7B | ₩28B |
| Total liabilities | ₩67B | ₩130B | ₩134B | ₩159B | ₩128B |
| Current liabilities | ₩60B | ₩122B | ₩88B | ₩108B | ₩60B |
| Borrowings | ₩33B | ₩61B | ₩66B | ₩81B | ₩53B |
| Total equity | −₩23B | −₩44B | ₩39B | ₩33B | ₩59B |
| Shareholders' equity | −₩23B | −₩45B | ₩38B | ₩32B | ₩58B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩3.5B | ₩6.7B | −₩14B | −₩11B | −₩1.7B |
| Capital spending | ₩28M | ₩1.8B | ₩5.7B | ₩39B | ₩14B |
| Free cash flow | ₩3.5B | ₩4.9B | −₩20B | −₩50B | −₩15B |
| Dividends paid | — | — | ₩990M | ₩1B | — |
Consolidated where available. Amounts in won.
Also known as: Eone Diagnomics Genome Center / EDGC / 245620 / KRX:245620
Source: KRX statistical information